Abstract: Phospholipases (PLC, PLD, and PLA) are essential in extracellular and intracellular signaling. This family of phosphopipid-hydrolizing enzymes can generate many bioactive lipid signaling molecules such as phosphatidic and lysophosphatidic acid, arachidonic acid, and diacylglycerol (DAG). The lipids produced from phospholipase enzyme activity regulate many cellular events considered hallmarks of cancerous behaviors in cells; including proliferation, migration, invasion, and angiogenesis.
Phospholipase D (PLD) belongs to a super family of phosphatase enzymes that hydrolyze the P-O bond. PLD specifically breaks down phosphatitdylcholine (PC) into choline and phosphatidic acid (PA), as shown in (Fig. 1) . PA then acts as a highly specific secondary messenger that mediates many important cellular functions such as cytoskeletal reorganization, vesicle trafficking, growth, and tumorigenesis [1] (Fig. 2) .
PLD Produces PA, an Activator of Several Cellular Signaling Pathways: mTOR
The mammalian target of rapamycin (mTOR) is a key pathway of cell growth and survival. PA, product of PLD, regulates mTOR activity by directly binding to its FK506-binding protein (FKBP12)-rapamycin-binding (FRB) domain [2] . PA competes with rapamycin for the same domain and prevents inhibition of mTOR. Elevated PLD activity is associated with rapamycin resistance in breast cancer cell lines [3] . Other molecules that inhibit mTOR including temsirolimus (with low clofarabine) for acute myeloid leukaemia (AML) [4] and other derivatives of rapamycin such as *Address correspondence to this author at the STEM Biotechnology Division, Roxbury Community College, Roxbury, MA 02120, USA; Tel: 617 427-0060 x 5215; E-mail: kastieglitz@rcc.mass.edu everolimus and deforolimus have also been studied and may be associated with elevated PLD activity [5] .
PA (Product of PLD PC Cleavage) Regulates S6K and 4EBP1
As shown in (Fig. 2) , the product of PLD-mediated PC cleavage PA directly regulates S6 kinase (S6K) and the eukaryotic initiation factor 4E binding protein 1 (4E-BP1). These two molecules are important downstream effectors of mTOR. 4EBP1 regulates mRNA translation and protein synthesis, while S6K controls various cell functions such as cell size, motility, and angiogenesis [6] . PA's regulation of S6K and 4EBP1 is independent of mTOR. Inhibition of PA production by 1-and 2-butanols blocks S6K activation and 4E-BP1 phosphorylation [2, 6] . The potential binding domains on S6K have been proposed [7] .
PA (Product of PLD PC Cleavage) Regulates RAC and RIP5K
PA produced by PLD promotes actin rearrangement through regulation of RAC and phosphatidylinositol 4-phosphate 5-kinase (PIP5K). Figure 2 PA binds to the Cterminal polybasic motif of Rac1 and encourages its translocation to the plasma membrane [8] . The presence of PA is essential to the production and activation of PIP5K, which also regulates cytoskeletal and membrane rearrangement [9] (Fig. 2) . 
RAF, RAS, and MAPK Pathway are Intertwined with PLD Cleavage of PC to PA Product
Evidence suggests that PA activates the mitogenactivated protein kinase (MAPK) pathway through the recruitment of Raf-1 from cytoplasm to the plasma membrane. Next, activated Raf-1 triggers MEK and ERK, which is an essential step in VEGF-induced angiogenesis. Inhibition of PLD with 1-butanol suppresses VEGF-induced ERK activation in endothelial cells [10] (Fig. 2) .
Figure 2 which summarizes some of the key interrelationships of these small molecules and protein effectors, illustrates the complexity of interaction that signaling molecules are engaged within mammalian cells. More specifically, PA and protein effectors such as RAS and RAF have a synergistic relationship in overall pathway of RAF. RAS is an activator of RAF. However, in addition to activating RAF, RAS promotes PC PA cleavage by activating PLD. This means that any extracellular growth hormone or stimulatory molecule of the EGF receptor stimulating RAF also potentially activates PLD cleavage of PC to PA. This places PLD in the center stage of the production of a cellular response that could be potentially cancer causing if left unchecked by cell cycle regulators.
RAS proteins are small GTPases that activate a variety of effector molecules, including RAF. Both molecules have been implicated to have increased expression and activation in certain cancers [11] . In addition, there is compelling biochemical evidence that RAS also enhances PLD activity indirectly, though the exact mechanism remains unclear [12] .
Key Regulators of mTOR TSC1 and TSC2 Indirectly Affect PLD Activity
The mTOR pathway has been implicated in various cancers, such as breast cancer, colorectal cancer, hepatocellular carcinoma, lung cancer, lymphoma, leukemias, melanoma, ovarian cancer, prostate cancer, and renal carcinoma [6] . The tumor suppressors tuberous sclerosis complex1 (TSC1) and TSC2 act as key regulators of mTOR. TSC1/TSC2 complex receives multiple upstream signals, such as growth factors, extracellular nutrient levels, and ATP, and inactivates the small GTPase Rheb, which serves as an activator of mTOR complex [13] . Two of the most important mTOR downstream effectors are 4EBP1 and S6K, which control various cell functions including cell growth, proliferation, and survival [6] . When not phosphorylated, 4EBP1 binds to eIF4E and inhibits its activity. After phosphorylation by mTOR, 4EBP1 releases eIF4E, which then initiates mRNA translation and protein synthesis. S6K phosphorylates the S6 ribosomal protein and multiple downstream molecules that are implicated with various cell functions such as cell size, motility, and angiogenesis [6] . Because TCC1 and TSC2 inhibit RHEB which activates mTOR and PLD, this also strongly ties mTOR and S6K to PLD regulation and suggests both mTOR and S6K negatively regulate PLD expression (green pathway in Fig. 2 ) [1] . The essential role of mTOR has been found in increasing MDM2 expression and subsequently suppresses p53 [14] .
Isoforms of Human PLD and Their Different Expression Patterns
There are two mammalian isoforms of PLD: PLD1 and PLD2. Although the two isoforms are structurally and functionally similar, their different expression in different tissues and subcellular structures suggests their distinct roles in cellular pathways. PLD1 is activated by a variety of mitogens and agonists and has little activity in resting cells; whereas PLD2 has high basal activity in most mammalian cells [13] . As summarized in Table 1 , PLD1 mRNA is rich in brain, heart, spleen, pancreas, liver, small intestine, ovary, placenta, and uterus, whereas PLD2 mRNA is rich in trachea, thyroid, thymus, spinal cord, ovary, placenta, uterus, and prostate [15] . PLD1 and PLD2 are also expressed differently at the subcellular level. PLD is present at the Golgi apparatus, endosomes, lysosomes, and secretory granules; PLD2 is primarily localized at plasma membrane [16] .
Correlation of Increased PLD Activity and Cancer
Increased PLD activity is observed in various cancers including breast, colon, gastric, kidney, and thyroid cancer. Expression of PLD2 is correlated with the tumor size and patient survival in colorectal carcinoma. Small molecular PLD inhibitors have been developed. In cell models, PLD inhibitors reduced cancer invasiveness and growth [17] . PLD generates survival signals that prevent apoptosis. Overexpression of PLD leads to increased expression of the p53 E3 ubiquitin ligase MDM2 and therefore suppresses the p53 response pathway [14] . In addition, PLD acts on the mTOR, a key pathway of cell growth and survival. Elevated PLD activity is associated with rapamycin resistance in breast cancer cell lines. PA competes with rapamycin and prevents inhibition of mTOR [3] . Inhibition of PLD blocks cytoskeleton reorganization, cell spreading and chemotaxis [18] . Therefore alleviating PLD activity has recently emerged as a new drug target for human cancer-cell invasiveness.
RHO (ROCK) Pathway and Other Human Diseases
For some time there has been evidence that RHO, an activator of ROCK (see Fig. 2 blue pathway) , also directly activates PLD in the intracellular pathway leading to actin reorganization. Although this leads to direct evidence that PLD is involved with the rearrangement of actin filaments, a forerunner of angiogenesis and cell migration in tumorigenesis [18] , these studies are beyond the scope of this focused review. The fact that PLD activation has long been associated with actin rearrangement strongly suggests that that in addition to cancer, PLD activation is associated with other pathological studies. Indeed this is the case as PLD has been implicated in various human diseases, including Alzheimer's disease [18, 20, 21] , myocardial ischemia [22, 23] , and acute pancreatitis [24] .
PART II OVERVIEW OF COMMERCIALLY AVAIL-ABLE PLD INHIBITORS AND NOVEL POTENTIAL PLD DRUG CANDIDATES
Both of the PLD isoforms PLD1 and PLD2 have 53% amino acid sequence identity and show different modes of activation and functional roles as shown by their differential expression ( Table 1) . Recently, extensive efforts have been focused on selective inhibition of one isoform over the other. Figure 3 shows the structures of successful dual and isoform selective PLD inhibitors in published in vitro and in vivo quantitative cell-based assays. Isoform selective PLD1 inhibitor 2 and PLD2 inhibitor 3 from (Fig. 3) , are structural modifications of dual PLD1/2 inhibitor halopemide, 1 [25] . In order to be PLD1 selective, the inhibitor requires a (S)-configuration on the methyl bearing carbon adjacent to the amide linkage [26] whereas a PLD2 selective inhibitor requires a spiro ring fused with the lactam [26, 27] . These inhibitors have been evaluated with pilot studies utilizing bacterial PLDs prior to in vivo drug studies with human PLDs to demonstrate that several bacterial PLD enzymes which are readily available to purchase from Sigma-Aldrich and EnzoLifeSciences, have cross-reactivity with the human PLDs despite some differences in both the amino acid sequence and specific details of the phospholipase mechanism. The results are summarized in Table 2 .
Both PLD from Streptomyces chromofuscus (PLD_Sc) and PLD from Streptomyces species strain pmf (PLD_Sp) exhibit a high specificity for phosphatidylcholine (PC) substrate cleaving PC to generate free choline and phosphatidic acid (PA). The PLD_Sp crystal structure has been solved, and the active site contains the highly conserved HKD repeats common within the PLD superfamily, including human and other mammalian PLD's as shown in (Fig. 4) [28] . Thus for structure based drug design, this bacterial PLD is an ideal starting point for the human PLD enzyme. In contrast, the cloned PLD_Sc is a non-HKD PLD that exhibits kinetic characteristics (such as specific metal co-factors) classifying as a member of the diverse family of metallo-phosphodiesterase/ phosphatase enzymes [29, 30] . However, despite limited sequence homology to the human species, PLD_Sc exhibits some compelling functional vesicle binding characteristic of the secreted mammalian and more specifically human GPI-PLD that is not yet readily available in recombinant form [31, 32] . Potent inhibitors of PLD_Sc and PLD_Sp which are based on 4-aminopyrazolopyrimidine core structure (Scheme 1) have been developed. These novel inhibitors were tested for inhibition in several biochemical assays using various forms of phospholipids from monomer substrate, micelle and SUVs, which are based on 4-aminopyrazolopyrimidine core structure (Scheme 1). 4-aminopyrazolopyrimidines have earlier been used as tyrosine kinase inhibitors [33] and dual inhibitors of tyrosine and phosphoinositide kinases [34] among other applications [35] .
Novel inhibitors designed for PLD enzymes lack a chiral center or a spiro ring structure, which is attractive from the synthetic point of view. The synthesis was accomplished from economic and commercially available starting materials. A considerable diversity in the basic core structure could be achieved by using various hydrazines and acyl/aroyl chlorides [33] .
SUMMARY
Over the past decade in biomedical research much work has been done on the "cross-talk" of intracellular signaling pathways. Human PLD has emerged as a "central player" as an integral part of other pathways activating inflammation, proliferation, angiogenesis, and migration, cell activities Fig. (4) . The Active Site of Streptomyces species PLD with Synthetic Product Short Chain Phosphatidic Acid: The crystal structure of PLD (PDB code 1V0Y) showing the active site of the Streptomyces species pmf and the co-crystallized shot chain synthetic product phosphatidic acid. Hydrogen bonding is shown to the highly conserved amino acids in the active site of the enzyme. This structure can be used in computer-based drug design due to the known high homology between the human active site amino acids and this bacterial enzyme. The molecular visualization tool Chimera was used with the PLD coordinates downloaded from the protein data bank (PDB) to prepare this figure.
directly linked to tumorigenesis and metastasis [16, 18] . As the role of PLD emerges identifying this enzyme as key component of cellular signaling and growth, more and more specific molecules are identified and developed in pharmaceutical research to inhibit this enzyme. It has become apparent that human phospholipase D is a specific and potent target for pharmaceutical studies to aid in the prevention of uncontrolled cellular growth and proliferation.
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